Search Results for: Nucleotides

October 1, 2019October 1, 2019

Antisense oligonucleotides might change the therapeutic landscape for Huntington’s disease.

Publication date: Oct 01, 2019 Paulsen, J.S. and Coffey, C.S. Antisense oligonucleotides might change the therapeutic landscape for Huntington’s disease. 06703. 2019 Lancet Neurol (18):10. Concepts Keywords Lancet The Lancet ... Read more

June 12, 2019June 12, 2019

Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington’s Disease.

Huntington's Disease Literature

Publication date: Jun 11, 2019 Huntington’s disease is a neurodegenerative disorder caused by a CAG repeat expansion in the first exon of huntingtin gene (HTT) encoding for a toxic polyglutamine ... Read more

May 18, 2019May 18, 2019

Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases.

Huntington's Disease Literature

Publication date: May 16, 2019 Nucleotide repeat disorders encompass more than 30 diseases, most of which show dominant inheritance, such as Huntington’s disease, spinocerebellar ataxias, and myotonic dystrophies. Yet others, ... Read more

April 20, 2019April 20, 2019

Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.

Melanoma Literature

Publication date: Apr 17, 2019 Skin cancer has always been and remains the leader among all tumors in terms of occurrence. One of the main factors responsible for skin cancer, ... Read more

April 7, 2018April 7, 2018

Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.

Huntington's Disease Literature

Publication date: Apr 01, 2018 On December 11 of 2017, Ionis Pharmaceuticals published a press release announcing dose-dependent reductions of mutant huntingtin protein in their HTTRx Phase 1/2a study in ... Read more

October 11, 2019October 11, 2019

Spliceosomal disruption of the non-canonical BAF complex in cancer.

Melanoma Literature

Publication date: Oct 09, 2019 SF3B1 is the most commonly mutated RNA splicing factor in cancer, but the mechanisms by which SF3B1 mutations promote malignancy are poorly understood. Here we ... Read more

October 10, 2019October 10, 2019

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease

Huntington's Disease News

Publication date: Oct 09, 2019 This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a ... Read more

October 10, 2019October 10, 2019

Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)

Multiple Sclerosis News

Publication date: Oct 09, 2019 Multiple Sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS), which is highly heterogeneous in terms of clinical symptoms, MS ... Read more

October 8, 2019October 8, 2019

Long non-coding RNAs in cutaneous biology and proliferative skin diseases: Advances and perspectives.

Melanoma Literature

Publication date: Oct 06, 2019 Advances in transcriptome sequencing have revealed that the genome fraction largely encodes for thousands of non-coding RNAs. Long non-coding RNAs (lncRNAs), which are a class ... Read more

October 4, 2019October 4, 2019

Is Huntington’s disease on the threshold of a new era in treatment?

Huntington's Disease Literature

Publication date: Oct 01, 2019 Sandy, S. and Richard, A. Is Huntington’s disease on the threshold of a new era in treatment? 06709. 2019 Neurodegener Dis Manag (9):5. Concepts Keywords ... Read more